Ligand-directed targeting vectors
AssigneeThe Regents of the University of California
InventorKouki MORIZONO
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Regents of the University of California
InventorKouki MORIZONO
Estimating the term…
Described is a targeting construct encoding a modified Sindbis virus envelope protein, comprising mutations in the E1, E2 and/or E3 proteins, fused with a monomeric biotin-binding molecule. Lentiviral vectors pseudotyped with the novel envelope proteins, such as E2 71 eMA and E2 71 mSAH, can be conjugated with biotinylated targeting ligands The conjugated ligands mediate specific binding and transduction of the target cell types. This lentiviral transduction system can be used to selectively deliver transgenes into specific cell types in vivo, which increases the numbers of vectors reaching the targeted cells and tissues and decreases adverse effects in non-targeted cells and tissues. The vectors transduce B cells without conjugation of targeting ligands. The B cell type most efficiently transduced in this manner is long-lived plasma cells, and thus can be used for long-term transgene expression.
A targeting construct comprising a nucleic acid sequence encoding a modified Sindbis virus envelope protein fused with a monomeric biotin-binding molecule, wherein the modified Sindbis virus envelope protein comprises mutant E2 and E3 proteins.
The method of claims 17, wherein the targeting ligand is an antibody that specifically binds CD3, Interlukin-7, protein L, CD40, and/or a B-cell receptor.
Dependencies are inferred from the claim text.